Michael Diem is Chief Business Officer at Century Therapeutics. Before joining Century, Mike was Senior Vice President of Business and Corporate Development at Amicus Therapeutics and prior to that, he held a similar role at Aevi Genomic Medicine. Earlier in his career, he was the Vice President and Global Head of Corporate Strategy and Corporate Development at AstraZeneca, where he was responsible for mergers and acquisitions, divestitures, and managed the company’s strategic investment activities and MedImmune Ventures. At GlaxoSmithKline, he led business development for the company’s rare disease business unit. He was also a partner in GSK’s corporate venture firm, SR One, Limited.
Education, Personal, and Fellowship
Mike holds a BA in biological sciences from Rutgers University and an MBA from the Waterhead School of Management at Case Western Reserve University. Mike earned an MD from the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, and completed his residency training at Duke University Medical Center. He currently serves as a board director at VenatoRx Pharmaceuticals and the Boys and Girls Clubs of Philadelphia.
Mike is a member of Class 12 and served his fellowship at SR One under mentors Phil Smith and Russell Greig.